Document is current
Any future updates will be listed below
-
Authors
Baker, Emma K. http://orcid.org/0000-0003-1165-0490
Arpone, Marta
Vera, Solange Aliaga
Bretherton, Lesley
Ure, Alexandra
Kraan, Claudine M.
Bui, Minh
Ling, Ling
Francis, David
Hunter, Matthew F.
Elliott, Justine
Rogers, Carolyn
Field, Michael J.
Cohen, Jonathan
Maria, Lorena Santa
Faundes, Victor
Curotto, Bianca
Morales, Paulina
Trigo, Cesar
Salas, Isabel
Alliende, Angelica M.
Amor, David J.
Godler, David E.
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (1049299 and 1103389, 1120561)
Medical Research Future Fund (MRF1141334)
Financial Markets Foundation for Children (2017 – 361)
- License Information
-
More Information
Article History
Received: 30 January 2019
Accepted: 7 November 2019
First Online: 26 December 2019
Ethics approval and consent to participate
: All procedures were approved by The Royal Children’s Hospital and INTA Human Research Ethics Committees (HREC #33066 and #15, respectively). All parents/caregivers provided written informed consent and those who were deemed cognitively able, also provided written informed consent.
: Not applicable
: David Eugeny Godler is named as an inventor on patent applications [PCT/AU2010/000169, PCT/AU2011/001024 and PCT/AU2014/000044] related to the technology developed to diagnose fragile X syndrome. All other authors declare no other competing interests.
